AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer patients with a specific genetic mutation and is already approved in the US and China for patients after chemotherapy failure. This deal expands AstraZeneca's lung cancer portfolio and aims to bring the treatment to patients worldwide. The transaction is expected to complete in the second half of 2026, pending regulatory approval.
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
AstraZeneca PLC shares fell over 6% following the failure of Wainua (eplontersen) in its Phase 3 ATTR-CM trial, which represents a significant lost revenue opportunity. Ionis Pharmaceuticals, which developed eplontersen and stands to earn royalties, ...
The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks ...
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
